Reddoch James F.
Known title: EVP & Chief Scientific OfficerCIK: 0001814872
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 100,000 | $4.1M | 9/28/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 100,000 | $4.2M | 6/8/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 75,000 | $3.1M | 5/27/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 75,000 | $3.0M | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.